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Certain sexually transmitted human papillomavirus (HPV) types are causally associated with the development of
cervical cancer. Our recent development of high-titer HPV pseudoviruses has made it possible to perform high-
throughput in vitro screens to identify HPV infection inhibitors. Comparison of a variety of compounds revealed that
carrageenan, a type of sulfated polysaccharide extracted from red algae, is an extremely potent infection inhibitor for
a broad range of sexually transmitted HPVs. Although carrageenan can inhibit herpes simplex viruses and some strains
of HIV in vitro, genital HPVs are about a thousand-fold more susceptible, with 50% inhibitory doses in the low ng/ml
range. Carrageenan acts primarily by preventing the binding of HPV virions to cells. This finding is consistent with the
fact that carrageenan resembles heparan sulfate, an HPV cell-attachment factor. However, carrageenan is three orders
of magnitude more potent than heparin, a form of cell-free heparan sulfate that has been regarded as a highly
effective model HPV inhibitor. Carrageenan can also block HPV infection through a second, postattachment heparan
sulfate–independent effect. Carrageenan is in widespread commercial use as a thickener in a variety of cosmetic and
food products, ranging from sexual lubricants to infant feeding formulas. Some of these products block HPV infectivity
in vitro, even when diluted a million-fold. Clinical trials are needed to determine whether carrageenan-based products
are effective as topical microbicides against genital HPVs.
Citation: Buck CB, Thompson CD, Roberts JN, Mu ¨ller M, Lowy DR, et al. (2006) Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2(7): e69. DOI: 10.
1371/journal.ppat.0020069
Introduction
Papillomaviruses are a diverse group of nonenveloped
DNA viruses that infect the skin and mucosal tissues of a
range of vertebrate species, including humans. A group of
genital mucosotropic human papillomavirus (HPV) types are
etiologic agents responsible for virtually all cases of cancer of
the uterine cervix, as well as a substantial fraction of other
ano-genital and head-and-neck cancers (reviewed in [1]).
Cancer-associated genital HPV types, as well as another
subset of HPV types associated with the development of
benign genital warts (condyloma accuminata), are generally
transmitted through sexual contact. Infection with genital
HPV types is very common, with an estimated lifetime risk of
infection of about 75% [2]. Although most genital HPV
infections are subclinical and self-limiting, a subset of
persistently infected individuals have lesions that progress
to premalignancy or cancer.
Recent meta-analyses have suggested that condoms are, at
best, only marginally effective for preventing the sexual
transmission of HPV [3,4]. However, a highly effective group
of prophylactic HPV vaccines are expected to become
publicly available in the near future [5]. Two possible
drawbacks to these vaccines are that they are expected to
be relatively expensive (at least initially) and are likely to be
papillomavirus type-restricted in their protection. Thus, the
vaccines may not initially be available to women in all parts of
the world and may not offer protection against all cancer-
associated HPV types. Inexpensive condom-compatible com-
pounds that could function as broad-spectrum topical
microbicides targeting sexually transmitted HPVs might
therefore serve as useful adjuncts to vaccination programs.
In vitro analysis of papillomavirus infection has historically
been hampered by the fact that key events in the late phase of
the viral lifecycle, such as the expression of the capsid
proteins L1 and L2, require cellular differentiation in the
upper layers of the stratiﬁed squamous epithelial tissues that
the viruses inhabit (reviewed in [6]). As a consequence,
papillomaviruses cannot replicate in conventional monolayer
cell cultures. Investigation of the assembly and entry phases
of the papillomavirus lifecycle has recently been simpliﬁed by
the development of high-yield methods for producing
papillomavirus-based gene transfer vectors, known as pseu-
doviruses (PsV), using conventional monolayer cell lines [7,8].
We have used PsV to develop a high-throughput screening
method to identify and compare compounds with the
potential to block papillomavirus infectivity in vitro [9].
Previous studies have shown that sulfated polysaccharides,
such as heparin, cellulose sulfate, and dextran sulfate, can
block the infectivity of papillomaviruses [10–12]. For many
classes of virus, including papillomaviruses, initial attachment
of the virion to cultured cell lines is thought to be mediated
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surface glycosaminoglycan (GAG) known as heparan sulfate
(reviewed in [13]). In general, sulfated polysaccharides are
thought to block viral infection by chemically mimicking
heparan sulfate, thereby competing against initial virion
attachment to the cell surface. Many previous studies have
used various types of heparin, a highly sulfated form of
heparan sulfate produced by mast cells, as a model inhibitor
of papillomavirus infectivity. In this report we show that
carrageenan, a class of sulfated polysaccharide extracted from
marine red algae (seaweed), inhibits the infectivity of genital
HPV PsV in vitro with nearly a thousand-fold greater potency
than heparin.
Carrageenan is in widespread commercial use as a
thickening agent for a variety of foods and cosmetic products,
including some brands of sexual lubricant. Since high-quality
carrageenan preparations (reviewed in [14]) appear to have a
good safety proﬁle for long-term vaginal use [15,16],
carrageenan might be useful as an inexpensive topical
microbicide for blocking the sexual transmission of HPV.
Results
Testing of Candidate Microbicides, including Carrageenan
Various candidate HPV infection inhibitors were tested
using a PsV-based inhibition assay [9]. The assay uses ﬂow
cytometric analysis to assess the inhibition of PsV-mediated
delivery of a green ﬂuorescent protein (GFP) reporter
plasmid into HeLa cells. HPV16, an exceptionally oncogenic
genital HPV type [17], was chosen as a model HPV for initial
experiments.
A wide variety of compounds were screened using the
inhibition assay (Tables 1 and 2). Although a variety of
nonsulfated polysaccharides failed to inhibit the infectivity of
the HPV16 PsV, most types of sulfated polysaccharides we
tested were inhibitory (Table 2). A standard heparin
preparation was inhibitory at doses similar to previous
reports [11,18]. However, preparations of intestine- and
kidney-derived heparan sulfate displayed no detectable
inhibition of PsV infectivity (Table 2). Since heparan sulfate
modiﬁcation is complex and varies depending on tissue
source (reviewed in [13]), it is possible that the noninhibitory
heparan sulfate preparations simply lack the proper chemical
features (e.g., a particular pattern of sulfation) required to
inhibit infection.
GAGs are unbranched polysaccharides primarily composed
of a monotonous series of characteristic disaccharide repeats.
GAGs can be divided into two broad categories: glucosami-
noglycans, such as heparan sulfate, and galactosaminoglycans,
such as chondroitin sulfate. As their names imply, a deﬁning
difference between the two GAG classes is their initial
incorporation of N-acetyl-glucosamine or N-acetyl-galactos-
amine saccharide units, respectively. Another important
difference between the two classes of GAG is that glucosami-
noglycans are linked in a series of 1,4 saccharide bonds,
whereas galactosaminoglycans are linked in an alternating
series of 1,3 and 1,4 bonds. Average structures for examples
of both types of GAG are shown in Figure 1.
Despite the substantial chemical differences between the
average structures of chondroitin 6-sulfate and heparin,
preparations of the two polysaccharides displayed similar
inhibitory effects against the HPV16 PsV (Table 2). In
contrast, a chondroitin 4-sulfate preparation was noninhibi-
tory (Table 2 and [11]), despite its high degree of chemical
similarity to chondroitin 6-sulfate. The results are consistent
with a previous report demonstrating that chondroitin 6-
sulfate (but not chondroitin 4-sulfate) competes against the
interaction of noninfectious capsids with immobilized hep-
arin [10].
Various types of carrageenan were by far the most potent
inhibitors identiﬁed in the screen (Table 2). Carrageenan is
an unbranched polysaccharide composed of galactose deriv-
atives arranged in an alternating series of 1,3 and 1,4
saccharide linkages reminiscent of the pattern seen in
galactosaminoglycans (Figure 1). In addition to having a
similar pattern of saccharide linkages, the typical sulfation
pattern of j-type carrageenan also closely resembles chon-
droitin 4-sulfate, with an average of one 4-O-linked sulfate
group per disaccharide repeat in both types of polysaccharide
(Figure 1). Despite these apparent chemical similarities to the
noninhibitory chondroitin 4-sulfate, j-carrageenan was an
extremely potent inhibitor, with 50% inhibitory concentra-
tion (IC50) values in the low ng/ml range.
Like heparin, k- and i-carrageenan types are more heavily
sulfated than most tissue-derived heparan sulfate (reviewed in
[13]). On average, these carrageenan types exhibited some-
what greater inhibitory potency than j-carrageenan (Table 2).
The Influence of Capsid Dose on Carrageenan Inhibitory
Effects
Assuming a typical carrageenan chain length of about a
thousand saccharide units (reviewed in [14]), the roughly 5 ng/
ml IC50 of i-carrageenan preparations corresponds to a
concentration of about 20 pM. The standard PsV-based
inhibition assay uses an HPV16 capsid inoculum of 1 ng of
the major capsid protein, L1, per milliliter (also ;20 pM).
Thus, the observed IC50s for the various types of carrageenan
occurred under conditions where there was only a slight mass
(or molar) excess of carrageenan over L1. If the inhibitory
effects of carrageenan were due to its direct binding to the
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Synopsis
Sexually transmitted human papillomavirus (HPV) infections are very
common. Although most HPV infections don’t cause noticeable
symptoms, persistent infection with some genital HPV types can
lead to cervical cancer or other anal/genital cancers. Another subset
of HPV types can cause genital warts. Recent studies have suggested
that condoms are not highly effective in preventing HPV infection.
Although HPV vaccines will soon become available, they probably
will not protect against all genital HPV types and will be too
expensive for use in the developing world. Inexpensive HPV-
inhibitory compounds (known as topical microbicides) might be
useful for blocking the spread of HPV. Using a newly developed cell
culture–based HPV inhibition test, we have discovered that an
inexpensive gelling agent called carrageenan is an unexpectedly
potent HPV infection inhibitor. Carrageenan is also under inves-
tigation as a topical microbicide targeting HIV and herpes viruses,
but it is a thousand times more effective against HPV in cell culture
tests. Interestingly, carrageenan is used as a thickener in some
commercially available sexual lubricants and lubricated condoms.
Several of these commercial lubricant products are potent HPV
inhibitors in our cell culture–infection system. Clinical trials are
needed to determine the effectiveness of carrageenan as a topical
microbicide against HPV.capsid, the IC50 might be expected to shift if excess capsids
were added to the assay. Consistent with this hypothesis, the
addition of ‘‘cold’’ capsids (i.e., PsV produced in the absence
of a GFP reporter plasmid) resulted in a dose-dependent
reduction in the apparent inhibitory potency of i-carra-
geenan preparation C4014 (Figure 2). This was not true for
the inhibitory effects of heparin, presumably because IC50s
for heparin occur under conditions of substantial inhibitor
excess, thus satisfying the law of mass action.
The observation that excess capsids can increase the IC50
for carrageenan strongly implies that the primary inhibitory
mechanism involves the direct binding of carrageenan to the
capsid. To further investigate this hypothesis, we performed
capsid pull-down experiments using i-carrageenan beads.
The results show that puriﬁed HPV16 capsids directly bind
carrageenan in phosphate buffer containing   0.4 M NaCl
(Figure 3, top panel).
Taken together, the results suggest the possibility that
carbohydrate-binding motifs on the capsid surface are highly
selective for a limited subset of sulfated polysaccharide
sequences. Although it is tempting to speculate that the i-
carrageenan structure depicted in Figure 1 represents an
ideal (or near-ideal) binding substrate, it should be noted that
the biochemistry of GAG and carrageenan modiﬁcation is
complex, and preparations of these molecules can contain
localized sequences of alternatively modiﬁed saccharide
residues that differ substantially from the idealized structures
depicted in Figure 1. Thus, the possibility that inhibition of
the PsV is mediated by a subset of atypical saccharide
sequences cannot be ruled out.
Inhibitory Effects of i-Carrageenan against Various
Papillomavirus Types
The effectiveness of sulfated polysaccharides for blocking
the in vitro infectivity of other viruses, such as HIV-1 and
dengue viruses, varies dramatically according to which viral
strain is used [19–21]. Thus, it seemed possible that the
inhibitory effects of carrageenan might also vary for different
papillomavirus types.
A variety of papillomavirus types are available as PsV. The
particle-to-infectivity ratios for stocks of different PsV types
vary substantially. We therefore used HPV16 cold capsids to
generate a standard curve comparing the IC50 of i-carra-
geenan inhibition to total capsid dose (Figure 4). Compared
to this standard curve, PsV based on three other cancer-
associated genital HPV types, 18, 31, and 45, exhibited a
similar degree of susceptibility to inhibition by i-carrageenan.
PsV based on HPV6, a relatively nononcogenic type that can
cause genital warts, also showed similar susceptibility to i-
carrageenan when compared to the HPV16 PsV.
Papillomaviruses are divided phylogenetically into more
than a dozen genera, with genital HPV types occupying a
single genus, alpha [22]. PsV are currently available for
papillomaviruses from three other genera: delta (bovine
papillomavirus type 1 [BPV1]), kappa (cottontail rabbit
papillomavirus [CRPV]) and beta (HPV5). In contrast to the
genital HPVs, PsV based on BPV1 and CRPV, which cause
Table 1. Inhibitory Effects of Nonpolysaccharide Compounds
Group Compound Supplier IC50 95% CI Cytotoxicity References
Antimicrobial peptides Cecropin A (porcine) AmericanPeptide — — .100
Cecropin A-Mellitin hybrid AmericanPeptide — — 11
Gramicidins A-D (B. Brevis) SigmaAldrich — — 1.2 [33,46]
Hecate Bachem 0.5 0.44–0.64 17 [47]
Lactoferrin (bovine) SigmaAldrich 13 12.1–13.4 .780 [48]
Lactoferricin B 4–14 fragment SigmaAldrich — — .15
Magainin-I SigmaAldrich — — .100 [25,49]
Melittin AmericanPeptide — — 4
Nisin SigmaAldrich — — 33 [50]
Parasin-I AmericanPeptide — — .100
Poly-(arginine-aminocaproyl) Bachem — — .100
Poly-arginine7 Bachem — — .100
Tachyplesin-I Bachem 7 6.3–8.6 100 [50,51]
Tuftsin Bachem — — .100
Redox agents Bacitracin SigmaAldrich — — .420 [52]
Buthionine sulfoximine (BSO) SigmaAldrich — — .7 [53,54]
BSO þ DNCB (cell pretreat) SigmaAldrich — — —
Dithiothreotol Invitrogen — — .100 [55]
1-Chloro-2,4-dinitrobenzene (DNCB) SigmaAldrich — — 7 [54,56]
Ellman’s reagent SigmaAldrich — — 1,300 [57]
2-Mercaptoethanol SigmaAldrich — — .100
Miscellaneous compounds Gelatin SigmaAldrich — — .100
Guanidine hydrochloride SigmaAldrich — — .475
Methyl ß-cyclodextrin SigmaAldrich — — .1,000 [58]
Nystatin SigmaAldrich — — 100 [59]
Polybrene SigmaAldrich 0.1 0.090–0.15 100 [38,39]
Polystyrene sulfonate, 1,430 kDa CarboMer 343 312–450 1,400 [12]
Sodium dodecyl sulfate QualityBiological — — 333 [25,60]
Values are given in lg/ml. Dashes imply that no inhibitory effect was observed at noncytotoxic doses.
DOI: 10.1371/journal.ppat.0020069.t001
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Carrageenan Inhibits Papillomavirusesnongenital skin lesions in host animals, were about a
hundred-fold less susceptible to inhibition by carrageenan
(Figure 4).
Surprisingly, HPV5, which typically infects nongenital skin
without causing overt symptoms, was not inhibited by i-
carrageenan or heparin, even at doses of up to 100 lg/ml.
Despite this extreme resistance to inhibition by carrageenan,
HPV5 PsV were found to bind directly to i-carrageenan beads
(Figure 3, bottom panel).
The same hierarchy of inhibition was seen for the various
papillomavirus types when the assay was performed using
other cell lines, including the spontaneously immortalized
human keratinocyte line HaCaT, human 293TT cells, or
murine C127 cells (Figure 4 and unpublished data).
To verify that i-carrageenan is active against an authentic
papillomavirus, we performed assays examining the focal
transformation of C127 cells by BPV1 [23,24]. These experi-
ments conﬁrmed that i-carrageenan can inhibit the infectiv-
ity of an authentic papillomavirus with an IC50 of between 1
and 10 lg/ml (unpublished data), consistent with capsid dose-
adjusted IC50s observed for BPV1 PsV.
The Influence of pH on Carrageenan Inhibitory Effects
Since carrageenan might have utility as a topical micro-
bicide for preventing the sexual transmission of HPVs, it is
important to consider the fact that human vaginal pH is
typically below 4.5 (reviewed in [25]). We therefore performed
inhibition assays examining the inhibitory effects of i-
carrageenan in culture medium buffered to pH 4.5 or 5.0
with lactic or acetic acid, respectively. i-Carrageenan re-
mained effective for blocking infectivity under acidic con-
ditions, with IC50 95% conﬁdence intervals (CIs) of 17–20, 13–
16, or 2.4–6.1 ng/ml at pH 4.5, 5.0, and 7.4, respectively.
i-Carrageenan Can Block Postbinding Events
To investigate the concept that i-carrageenan might block
infectivity by preventing the initial attachment of capsids to
cells, we performed ﬂow cytometric analysis of cells exposed
to ﬂuorescently labeled HPV16 capsids in the presence of
various doses of carrageenan. As expected, i-carrageenan
blocked the binding of labeled capsids at concentrations
similar to those capable of blocking infectivity when stand-
ardized for capsid dose (Figure 4). Similar results were
obtained using HaCaT cells as a binding target (unpublished
data).
In addition to blocking the initial attachment of virions to
cells, heparin can also block the infectivity of cell-bound PsV
for many hours after initial attachment to cells [11]. To
investigate the possibility that i-carrageenan also exerts
additional, postattachment inhibitory effects on PsV infec-
tivity, we performed time course experiments in which cells
with prebound PsV were exposed to i-carrageenan. As seen in
Table 2. Inhibitory Effects of Polysaccharide Compounds
Group Compound Catalog Number IC50 95% CI
Nonsulfated polysaccharides Agarose 15510 — —
Alginic acid (algin) A2033 18 12–26
Carboxymethyl cellulose C4888 — —
Cellulose acetate phthalate 328073 — —
Chitosan 448877 — —
Guar G4129 — —
Inulin I2255 — —
Locust bean gum 62631 — —
Mannan M7504 — —
Pectin P7536 — —
Xanthan gum G1253 — —
Sulfated polysaccharides Agar 0140–01 0.27 0.22–0.33
i-Carrageenan 22045 0.006 0.0050–0.0063
i-Carrageenan, type II C1138 0.005 0.0042–0.0049
i-Carrageenan, type V C3799 0.006 0.0044–0.0080
i-Carrageenan, type V
a C4014 0.004 0.0036–0.0046
j-Carrageenan 22048 0.044 0.037–0.052
j-Carrageenan, type III C1263 0.013 0.011–0.016
j/k-Carrageenan, type I C1013 0.021 0.020–0.022
k-Carrageenan 22049 0.010 0.0093–0.011
k-Carrageenan, type IV C3889 0.005 0.0039–0.0058
Cellulose sulfate 17781 0.22 0.21–0.24
Chondroitin 4-sulfate C9819 — —
Chondroitin 6-sulfate C4384 1.4 1.0–1.9
Dermatan sulfate C3788 33 31–35
Dextran sulfate, .500 kDa D6001 0.16 0.15–0.17
Fucoidan F5631 1.1 0.25–4.7
Heparan sulfate (bovine kidney) H7640 — —
Heparan sulfate (porcine intestine) H9902 — —
Heparin H4784 1.3 1.3–1.4
Values are given in lg/ml.
Dashes imply that the compound was noninhibitory at doses  100 lg/ml.
None of the compounds scored as cytotoxic at doses  100 lg/ml, except cellulose sulfate, which was cytotoxic at doses  11 lg/ml.
aChosen as a model carrageenan for follow-up studies.
DOI: 10.1371/journal.ppat.0020069.t002
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Carrageenan Inhibits Papillomavirusesthe 2-h timepoint in Figure 5, cell-bound HPV16 PsV
remained entirely susceptible to inhibition by somewhat
higher doses of i-carrageenan. Half of the infectious titer
remained susceptible to inhibition by i-carrageenan for up to
12 h after initial binding to cells. Similar results were
observed when HaCaT cells were used as an infection target
(unpublished data). The results demonstrate that, in addition
to blocking the initial interaction of capsids with cells, i-
carrageenan also exerts a postattachment inhibitory effect on
infectivity.
Postbinding Inhibitory Effects of i-carrageenan Do Not
Involve Heparan Sulfate
The postattachment inhibitory effects of i-carrageenan
could be due either to displacement of capsids from heparan
sulfate proteoglycans (HSPGs), or due to disruption of HSPG-
independent steps in the viral infectious pathway. To address
this issue, we made use of a GAG-negative cell line known as
pgsA-745. The line was created by chemical mutagenesis of
Chinese hamster ovary (CHO) cells, resulting in the dis-
ruption of a xylosyltransferase gene that is required for the
ﬁrst peptide glycosylation step in the synthesis of all GAGs,
including heparan sulfate [26]. Fluorescent capsid binding
studies (unpublished data) conﬁrmed a previous report
showing that pgsA-745 cells bind HPV capsids relatively
poorly compared to parental CHO cells [10]. Despite this
reduction in bulk capsid binding, pgsA-745 cells could be
infected to the same extent as parental CHO cells if a 50-fold
higher inoculum of HPV16 PsV was used (data not shown).
Using these conditions, we examined the effects of i-
carrageenan on HPV16 PsV prebound to the two cell lines for
3 h. Both cell lines displayed similar infectious IC50 values,
with 95% CIs of 14–61 ng/ml for CHO and 13–21 ng/ml for
pgsA-745. The result directly demonstrates that i-carra-
geenan can disrupt steps in the HPV16 infectious pathway
that do not involve HSPGs.
PsV Inhibition by Consumer Products Containing
Carrageenan
The widespread use of carrageenan in various consumer
products led us to wonder whether lubricants intended for
sexual use might employ carrageenan as a gelling agent.
Internet searches revealed a number of sexual lubricant
products that list carrageenan, or other algal polysaccharides,
as ingredients. Although most lubricated condom brands
(and some sexual lubricant brands) do not publicize their
ingredients, one condom brand, Chapeau Crystal Carra-
geenan (Fuji Latex Co., Tokyo, Japan), advertises its use of a
carrageenan-based lubricating gel [27].
Various sexual lubricant gels were subjected to testing in
the HPV16 PsV inhibition assay. Several of the lubricant
Figure 1. Polysaccharide Structures
Idealized average structures of the disaccharide repeat units of various
sulfated polysaccharides. Ac ¼ acetyl, R ¼ [H or SO3
 ], R9 ¼ [H, Ac, or
SO3
 ]. Structures adapted from [13], http://www.lsbu.ac.uk/water/hycar.
html, and http://www.sigmaaldrich.com.
DOI: 10.1371/journal.ppat.0020069.g001
Figure 2. Capsid Dose Influences Carrageenan IC50
Inhibition assays were performed using a standard dose of GFP-expressing HPV16 PsV in the presence of increasing doses of cold capsids. Overall capsid
dose is given as the final concentration of the major capsid protein, L1, in the culture medium.
DOI: 10.1371/journal.ppat.0020069.g002
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Carrageenan Inhibits Papillomavirusesproducts were extremely potent inhibitors, with IC50 values
occurring at dilutions of a few million–fold (Table 3). Two
highly inhibitory European brands, Bioglide and Bioglide
Anal, list carrageenan as an ingredient. The other compo-
nents in these two products, water, glycerol, and xanthan
gum, were noninhibitory when tested individually (Tables 2
and 3).
One US product, Divine N8 8, uses the term ‘‘natural kelp
extract’’ in its ingredient list. Although it is not clear what
type of algal polysaccharide this term refers to, the high
potency of Divine N8 8 in the HPV16 PsV inhibition assay
strongly suggests that the product contains carrageenan. An
unscented version of the product, Divine N8 9, does not list
ingredients on its packaging or at its manufacturer’s website,
but its high potency suggests that it, too, may contain
carrageenan. The inhibition curves for the Bioglide and
Divine lubricants were similar to what would be expected if
the products were composed of roughly 1%–3% carrageenan,
a typical concentration range used to achieve gelation.
The packaging of a third US product, ForPlay Gel Plus, lists
carrageenan as its ﬁfth ingredient, behind several nonsulfated
thickening agents. ForPlay Gel Plus did not display detectable
inhibitory effects, even at dilutions as little as a hundred-fold.
It is possible that ForPlay Gel Plus either contains very little
carrageenan, or contains a less-inhibitory type of carra-
geenan. Alternatively, interactions between carrageenan and
other compounds in ForPlay Gel Plus may abrogate the
inhibitory effects of the carrageenan.
Lubricant brands containing other algal polysaccharides,
such as agar and algin, were less effective for blocking the
HPV16 PsV in the inhibition assay, consistent with the
observation that these compounds are less inhibitory than
carrageenan when tested individually (Table 2).
Several lubricant gels that do not contain sulfated poly-
saccharides were ineffective for blocking the HPV16 PsV at
tested doses. Ortho Options Conceptrol, a contraceptive gel
containing the detergent spermicide nonoxynol-9, does not
contain sulfated polysaccharides. The fact that Conceptrol
was ineffective for blocking the HPV16 PsV at noncytotoxic
doses (Table 3) is consistent with a previous report
demonstrating that nonoxynol-9 is not effective for blocking
papillomavirus infectivity [28].
Another common use for carrageenan is as a stabilizing
agent in milk-based products, including infant feeding
formulas. The use of infant formulas containing carrageenan
might thus be a factor in vertical transmission of HPVs, since
such transmission could involve establishment of initial
infection in infants’ oral mucosa. We therefore tested several
brands of infant formula using the HPV16 PsV inhibition
assay. Formulas containing carrageenan displayed signiﬁcant
inhibitory effects, while fresh milk and infant formulas
without carrageenan did not display detectable inhibitory
effects at tested doses (Table 3).
Discussion
In this report we demonstrate that carrageenan, an
inexpensive commercial thickening agent extracted from
seaweed, is an exceptionally potent inhibitor of papilloma-
virus infectivity in vitro. Carrageenan was found to be active
against a range of common sexually transmitted HPV types
that can cause cervical cancer and genital warts. Since
carrageenan is generally recognized as safe for food and
topical applications, it is an appealing candidate for use as a
broad-spectrum topical microbicide to block HPV trans-
mission.
Figure 4. Standardized Carrageenan IC50 for Various Papillomavirus
Types
Points represent carrageenan IC50 of infectivity, except for empty red
triangles, which represent the carrageenan IC50 of cell binding for HPV16
capsids covalently linked to a fluorescent dye. Empty circles represent
carrageenan IC50 of infectivity observed using HaCaT cells instead of
HeLa cells. Error bars represent the 95% CI for the IC50.
DOI: 10.1371/journal.ppat.0020069.g004
Figure 3. Capsids Bind Carrageenan
Carrageenan beads were incubated with HPV16 or HPV5 capsids in
buffers with the NaCl concentration shown. The beads were washed,
then bound capsids were eluted and visualized in stained SDS-PAGE gels.
Bovine serum albumin (BSA, 65 kDa) was used as a control for
nonspecific binding to the beads. For HPV16, an L2 band can be seen
above the L1 band.
DOI: 10.1371/journal.ppat.0020069.g003
Figure 5. Carrageenan Addition Time Course
Cells were incubated with HPV16 PsV for 2 h, followed by washout of the
virus inoculum. Carrageenan was added at the timepoints shown, where
time zero represents initial PsV inoculation.
DOI: 10.1371/journal.ppat.0020069.g005
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Carrageenan Inhibits PapillomavirusesSome, but not all, carrageenan-containing over-the-coun-
ter sexual lubricant gels we tested were extremely effective
for blocking the infectivity of an HPV16 reporter pseudovirus
in vitro. These results raise the possibility that use of such
lubricant products, or condoms lubricated with carrageenan-
based gels, could block the sexual transmission of HPV.
However, in the absence of clinical efﬁcacy data, it would be
inappropriate to recommend currently available products for
use as topical microbicides.
Carrageenan is also active in vitro and in murine model
systems against other viruses, including herpes simplex
viruses and some strains of HIV-1 [29–34]. However, in vitro
IC50 values for carrageenan inhibition of herpes simplex virus
and HIV-1 infectivity are about a thousand-fold higher than
the IC50s we have observed for carrageenan inhibition of
genital HPVs in vitro.
It is important to emphasize that cell culture systems may
not fully represent some aspects of HPV infection of
keratinocytes in vivo. However, our group has recently
developed a pseudovirus-based murine genital challenge
model for initial HPV infection (unpublished data). This
animal model system should be useful for investigating of the
potential efﬁcacy of carrageenan for blocking HPV trans-
mission in vivo.
A clinical trial focused on the effectiveness of a j/k-
carrageenan preparation as a topical microbicide is currently
in progress in South Africa. A recent patent application by
the trial’s organizers (http://www.popcouncil.org) contains a
claim of carrageenan as a papillomavirus inhibitor, but the
potency of the inhibitory effect was not indicated [35]. Since
the principal focus of the ongoing trial is the efﬁcacy of
carrageenan against HIV-1, it may be necessary to develop
additional clinical trials speciﬁcally focused on the in vivo
efﬁcacy of well-deﬁned carrageenan preparations against
HPVs. The high rate of acquisition of genital HPV infection
in young adult populations (reviewed in [2]) might make it
possible to perform short-duration clinical efﬁcacy trials with
relatively small numbers of human subjects.
Our results show that the principal mechanism by which
carrageenan blocks papillomavirus infectivity is via the direct
binding of carrageenan to the viral capsid. The binding of
carrageenan appears to block interactions between the capsid
and cell-surface HSPG attachment factors. Although the
presence of HSPGs on the cell surface signiﬁcantly enhances
papillomavirus binding to and infection of most types of
cultured cell lines [10,11,36,37], in this report we have used
GAG-negative cells to demonstrate conclusively that HSPG
attachment factors are not strictly required for infection to
occur. A similar situation has been described for certain
strains of HIV-1, particularly lab-adapted HIV-1 strains, for
which HSPGs are thought to serve as attachment factors that
facilitate (but are ultimately dispensable for) the in vitro
infection of some cultured cell lines [38,39].
In addition to blocking the initial interaction between
papillomavirus virions and HSPGs, carrageenan also exerts a
second HSPG-independent inhibitory effect. This secondary
inhibitory effect could be due to occlusion of virion surfaces
involved in binding to cellular proteins involved in the
infectious process. Alternatively, carrageenan might interfere
with the development of needed conformational changes
within the virion. Since it is possible that HPVs use
alternative, non-HSPG attachment factors in vivo [36,37],
the existence of a postattachment, GAG-independent inhib-
itory effect increases the likelihood that carrageenan might
ultimately be effective as a topical microbicide against HPVs.
Although carrageenan was highly effective for neutralizing
ﬁve different genital HPV types in vitro, it was substantially
less potent against several papillomavirus types tropic for
nongenital skin. Since common genital HPVs occupy a single
genus, and the three nongenital papillomavirus types we have
Table 3. Inhibitory Effects of Consumer Products
Group Product Manufacturer Compound of Interest IC50 95% CI
Lubricant Aquaglide Bioglide — — —
Bioglide Bioglide Carrageenan 6 3 10
6 4.6–6.7 3 10
6
Bioglide Anal Bioglide Carrageenan 7 3 10
6 6.1–7.7 3 10
5
Divine N8 8 DivineTimes Natural kelp extract 8 3 10
6 6.8–8.7 3 10
6
Divine N8 9 DivineTimes Unknown 1 3 10
7 9.1–11 3 10
6
ForPlay Gel Plus Trimensa Carrageenan — —
Glycerol (glycerin) SigmaAldrich — — —
Intimate Infusions Almost Naked SacredMomentsProducts Agar 2,400 1,800–3,100
K-Y Jelly JNJ — — —
Ortho Options Conceptrol Ortho-McNeilPharmaceutical Nonoxynol-9 — —
Stimula Stimula-US Algin 560 360–870
Surgilube Fougera — — —
Infant formula Carnation Nonfat Dry Milk Nestle — ,100 —
Enfamil (concentrate) MeadJohnson Carrageenan 3 3 10
4 2.5–2.9 3 10
4
Enfamil (dry) MeadJohnson — ,100 —
Fat-free milk Safeway Lactoferrin ,100 —
Good Start Supreme (concentrate) Nestle — ,100 —
Similac Advance (ready) Abbott Carrageenan 3 3 10
4 3.1–3.6 3 10
4
Values are expressed as fold dilution.
None of the products scored as cytotoxic at dilutions  100-fold, except Conceptrol, which was cytotoxic at dilutions  900-fold and Surgilube, which was cytotoxic at the 100-fold dilution.
The results do not imply endorsement or nonendorsement of any product.
DOI: 10.1371/journal.ppat.0020069.t003
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Carrageenan Inhibits Papillomavirusestested are phylogenetically distant from the genital types [22],
it is tempting to speculate that all HPVs tropic for the genital
mucosa would be comparably susceptible to inhibition by
carrageenan. However, the possibility that some genital HPVs
might exhibit natural resistance to inhibition by carrageenan
would be an important factor to consider in the design of
clinical efﬁcacy trials.
Recurrent respiratory papillomatosis is a rare but debili-
tating HPV-induced condition involving the formation of
large benign tumors on airway surfaces. The main treatment
for the disorder is surgical removal of recurring obstructive
masses. Juvenile onset recurrent respiratory papillomatosis
(JORRP) is thought to be the result of vertical transmission of
genital wart-associated HPV types 6 or 11 during birth
(reviewed in [40]). The fact that some common infant
formulas contain carrageenan raises the possibility that such
formulas might function as inhibitors of the initial establish-
ment of papillomavirus infection in newborns’ oro-laryngeal
epithelium [41]. Since human breast milk offers infants a wide
variety of health beneﬁts and JORRP is rare (roughly four
cases per 100,000 births), it would be inappropriate to
consider using infant formula for the purpose of preventing
JORRP. However, the apparent safety of infant formulas
containing carrageenan suggests that a pharmaceutical-grade
carrageenan-based gel might be safe for perinatal cervico-
vaginal application. The infrequency of JORRP, and its long
initial latency period, would make it an impractical endpoint
to use for clinical efﬁcacy trials investigating the application
of carrageenan-based gels. However, asymptomatic vertical
transmission of genital HPV types, which is thought to be
relatively common (reviewed in [42]), might be used as a
surrogate endpoint that could readily be monitored by HPV
DNA testing of infant buccal swabs.
Materials and Methods
Cell culture. All cell lines were cultured in DMEM (Invitrogen,
Carlsbad, California, United States) supplemented with 10% 56 8C
heat-inactivated fetal calf serum (Hyclone, South Logan, Utah, United
States), nonessential amino acids, and Glutamax-I (Invitrogen)
(DMEM-10). CHO-K1 and pgsA-745 (American Type Culture Collec-
tion, Manassas, Virginia, United States) [26] were maintained in
DMEM-10 supplemented with an additional 100 lM proline.
Pseudovirus production. Nucleotide maps of plasmids used in this
work, as well as detailed protocols, are available at our laboratory
website (http://home.ccr.cancer.gov/lco/default.asp). Various types of
GFP-expressing pseudoviruses were produced according to previ-
ously described methods [7–9,43,44]. Brieﬂy, 293TT cells were
transfected with plasmids expressing the papillomavirus major and
minor capsid proteins, L1 and L2, together with a GFP-expressing
reporter plasmid, pfwB [8]. All PsV were produced using codon-
modiﬁed L1 and L2 genes, except for HPV31 PsV, which used
expression constructs based on wild-type L1 and L2 open reading
frames. The high particle-to-infectivity ratio of HPV31 PsV stocks
(Figure 4) is likely due to relatively poor expression of L2
(unpublished data). Codon-modiﬁed HPV45 L1 and L2 genes
(p45L1w and p45L2w) were constructed based on sequencing of an
HPV45 molecular clone. HPV16 PsV were produced using a
previously unreported bicistronic L1/L2 expression plasmid,
p16sheLL. Capsids were allowed to mature overnight in cell lysate,
then puriﬁed using Optiprep gradients. The L1 protein content of
PsV stocks was determined by comparison to bovine serum albumin
standards in Coomassie-stained NuPAGE gels.
Fluorescently tagged capsids were generated by covalently con-
jugating Alexa Fluor 488 carboxylic acid, succinimidyl ester (Molec-
ular Probes, Eugene, Oregon, United States) to HPV16 PsV, according
to the manufacturer’s instructions. Cell-binding inhibition results
were also conﬁrmed using ﬂuorescent capsids generated by incorpo-
ration of an L2-GFP fusion protein [9]. Both types of ﬂuorescent
capsid displayed particle-to-infectivity ratios similar to wild-type
HPV16 PsV (unpublished data).
Inhibition assays. Nonpolysaccharide candidate inhibitors were
purchased from the suppliers shown in Table 1. Polysaccharides were
purchased from Sigma-Aldrich (St. Louis, Missouri, United States),
except for agarose (Invitrogen), agar (Difco, Detroit, Michigan,
United States), and cellulose sulfate (Acros, Geel, Belgium).
Compounds were tested using a previously described PsV-based
papillomavirus inhibition assay [9]. Brieﬂy, HeLa cells were plated at
6,000 cells/well in 50 ll of medium in 96-well plates. Candidate
inhibitors were dissolved at 1–10 mg/ml (or reconstituted as directed
by manufacturer) in sterile water or appropriate solvent, then
subjected to a ten-point three-fold serial dilution covering an
appropriate concentration range. Diluted candidate inhibitor (50
ll) was added to preplated HeLa cells, followed by 50 ll of diluted
PsV stock. The cells were incubated for 24 h, fed by addition of 100 ll
of DMEM-10, then subjected to ﬂow cytometric analysis 48–56 h after
infection. IC50 values and 95% CI were determined using Prism
(GraphPad Software, San Diego, California, United States) to
calculate a variable slope sigmoidal dose-response curve.
PsV doses were calibrated such that between 5% and 20% of cells
scored as GFP
þ when no inhibitors were added. For HPV16, a
standard dose with a ﬁnal concentration of 1 ng/ml L1 (about 750
capsid equivalents of L1 per cell) resulted in ﬂuorescence of about
10% of cells in the ‘‘no inhibitor’’ condition. Other papillomavirus
types were used at the ﬁnal L1 concentrations shown in Figure 4.
HPV5 PsV infection of HeLa cells was performed with a dose of 35 ng/
ml L1. Relative to HeLa cells, appropriate infection of HaCaT cells
required a two- to three-fold higher capsid dose for HPVs 16, 18, and
45 and a two- to three-fold lower capsid dose for HPVs 5 and 6.
Cytotoxicity was deﬁned as a .50% reduction in the net turnover
of the metabolic substrate WST-1 (Roche, Indianapolis, Indiana,
United States) and/or by the appearance of dramatic alterations in
the microscopic appearance of cell morphology at the time of
harvest.
The effect of acidic conditions on the inhibitory activity of i-
carrageenan was analyzed by inoculating HeLa cells with HPV16 PsV
(1 ng/ml L1) together with various doses of i-carrageenan in
bicarbonate-free RPMI (Invitrogen) buffered to pH 7.4 with 10 mM
HEPES, pH 5.0 with 10 mM acetic acid, or pH 4.5 with 10 mM lactic
acid. The virus inoculum was removed after 2 h at 37 8C (ambient
CO2) and replaced with DMEM-10 without carrageenan. Cell viability
and PsV infectivity under acidic conditions were not signiﬁcantly
different from the neutral RPMI control.
Inhibition of capsid-to-cell binding was analyzed using HeLa and
HaCaT cells detached using Cellstripper (Mediatech, Herndon,
Virginia, United States), a proprietary, nonenzymatic chelating
buffer. Suspended cells (3 3 10
4 per condition) were incubated for
1 h at 37 8C with ﬂuorescent capsids in a 150 ll volume of DMEM-10
supplemented various doses of i-carrageenan. The cells were then
washed and subjected to ﬂow cytometric analysis. Binding IC50 was
calculated based on net geometric mean ﬂuorescence intensity using
Prism software.
Time course analyses were performed in 96-well plates by
incubating HPV16 PsV (1 ng/ml L1) with preplated HeLa cells for 2
ha t3 78C, followed by two washes to remove unbound virus. Various
doses of carrageenan in DMEM-10 were then added to the cultures at
the timepoints shown in Figure 5. For the 0-h timepoint, carrageenan
was added to cultures immediately prior to virus inoculation, and a
second carrageenan dose was added after washout of the inoculum.
For the 2-h timepoint, carrageenan was added immediately after
washout of the inoculum.
CHO-K1 and pgsA-745 cells were preplated overnight at 50,000
cells/well in 24-well plates. Cells were inoculated with 250 ll of HPV16
PsV at 45 ng/ml L1 (pgsA-745) or 0.9 ng/ml L1 (CHO-K1). The plates
were incubated at 37 8C and gently swirled every 20 min for 3 h. The
cells were then washed, and placed in 0.5 ml of medium containing
various doses of carrageenan. The cultures were fed by addition of 2
ml of medium with no carrageenan after 24 h, and subjected to ﬂow
cytometric analysis 56 h after initial PsV inoculation.
Capsid pull-down experiments. Crosslinked 3% i-carrageenan
beads (Bioscience Beads, West Warwick, Rhode Island, United States)
were used to perform HPV5 and HPV16 carrageenan direct-binding
studies. HPV5 or HPV16 L1 (2 lg in the form of puriﬁed PsV) were
incubated for 1 h at room temperature with 50 ll of carrageenan
bead slurry pre-equilibrated into 1 ml of Dulbecco’s PBS supple-
mented with 0.01% Tween-80 [45] and various concentrations of
NaCl. BSA (4 lg) was used as a negative control. The beads were
washed 3 3 10 min in Dulbecco’s PBS containing appropriate
concentrations of NaCl, followed by a ﬁnal wash with plain
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Carrageenan Inhibits PapillomavirusesDulbecco’s PBS. The beads were eluted by incubation at 65 8Ci n
NuPage Load Dye (Invitrogen) with 8% 2-mercaptoethanol. Samples
(10 ll out of about 75 ll total) were separated on NuPage gels
(Invitrogen) and visualized using SYPRO Ruby Stain (Molecular
Probes). Comparison of the samples to 1 ll of BenchMark Protein
Ladder (Invitrogen) suggested an overall L1 recovery of roughly 75%
in the 0.15 M NaCl condition (Figure 3).
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